Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Dopamine D2 Receptors and Extracellular Dopamine With (18F)Fallypride, D-amphetamine, and Alpha-Methyl-Para-Tyrosine in Healthy Subjects
NCT00062946Phase 2Completed
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 18F-fallypride, sponsored by National Institute of Mental Health. Primary endpoints: Baseline dopamine levels and Stimulant-induced dopamine release. Started Jun 2003; status: completed.
02
Drugs
18F-fallypride
Beyond the preview
Go deeper on NCT00062946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062946.